Long-term oncological outcomes of pelvic lymph node dissection during radical prostatectomy
DOI:
https://doi.org/10.2340/sju.v61.45236Keywords:
Urology, radical prostatectomy, prostate cancer, lymph node dissection, patient outcome, DanProstAbstract
Purpose: Lymph node dissection during radical prostatectomy (RP) remains under debate due to an unclear impact on oncological outcomes. Here, we investigate long-term oncological events after RP +/- pelvic lymph node dissection (PLND).
Methods: All patients who had an RP from 2006 to 2021 (N=15,515) in the Danish Prostate Registry were included. Cumulative incidence of biochemical failure (BF), subsequent treatment, and prostate cancer-specific death by the Aalen Johansen estimator from the time of RP were compared for men without lymph nodes removed (pNx), without positive lymph nodes (pN0), and with lymph node invasion (pN1). Area under the curve (AUC) of the receiver operating characteristic was used to determine the added value of PLND for outcome discrimination.
Results: The 15-year incidences of BF were pNx = 22% (95% confidence interval [95CI]: 20–23), pN0 = 37% (95CI: 35–39), and pN1 = 70% (95CI: 65–76). Fifteen-year incidences of subsequent treatment were 19% (95CI: 18–20), 31% (95CI: 29–33), and 84% (95CI: 79–89) for men with pNx, pN0, and pN1. Fifteen-year risk of prostate cancer-specific death was 2.1% (95CI: 1.6–2.6), 5.5% (95CI: 4.6–6.5), and 25% (95CI: 18–32) for men with pNx, pN0, and pN1. The AUC for the 10-year BF increased from 74% (95CI: 72–77) to 76% (95CI: 73–78) with the addition of pN0/pN1 in the model. The main limitation was the inability to differentiate the number of malignant nodes removed.
Conclusion: Men with positive lymph nodes after PLND faced a high risk of BF, subsequent treatment, and prostate cancer-specific death. As the addition of PLND did not substantially improve the discriminative ability, the added benefit of PLND is likely limited. The side effects of PLND should be considered in relation to its possible advantages.
Downloads
References
Fossati N, Willemse PPM, Van den Broeck T, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol. 2017;72:84–109. https://doi.org/10.1016/j.eururo.2016.12.003 DOI: https://doi.org/10.1016/j.eururo.2016.12.003
Messing E, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):246–247. https://doi.org/10.1056/NEJM199912093412401 DOI: https://doi.org/10.1056/NEJM199912093412401
Briganti A, Chun FKH, Salonia A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50(5):1006–1013. https://doi.org/10.1016/j.eururo.2006.08.015 DOI: https://doi.org/10.1016/j.eururo.2006.08.015
Bader P, Burkhard FC, Markwalder R, et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol. 2002;168(2):514–518. https://doi.org/10.1016/S0022-5347(05)64670-8 DOI: https://doi.org/10.1016/S0022-5347(05)64670-8
Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am. 2003;30(2):377–401. https://doi.org/10.1016/S0094-0143(02)00176-3 DOI: https://doi.org/10.1016/S0094-0143(02)00176-3
Lestingi JFP, Guglielmetti GB, Trinh QD, et al. Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial. Eur Urol. 2021;79(5):595–604. https://doi.org/10.1016/j.eururo.2020.11.040 DOI: https://doi.org/10.1016/j.eururo.2020.11.040
Stroomberg HV, Larsen SB, Lanthén GS, et al. Danish Prostate Registry (DanProst) – an updated version of the Danish Prostate Cancer Registry, Methodology , and Early Results. 2023. https://pubmed.ncbi.nlm.nih.gov/37702859/ DOI: https://doi.org/10.1007/s10916-023-01991-8
Stroomberg HV, Larsen SB, Kjær Nielsen T, et al. Outcomes of Biopsy Grade Group 1 prostate cancer diagnosis in the Danish population. Eur Urol Oncol. 2024 Aug;7(4):770-777 https://doi.org/10.1016/j.euo.2023.10.005 DOI: https://doi.org/10.1016/j.euo.2023.10.005
Stroomberg HV, Friberg AS, Helgstrand JT, et al. The impact of positive surgical margins on salvage radiation or androgen deprivation therapy following radical prostatectomy – a nationwide study. Acta Oncol (Madr). 2021;60(5):620–626. https://doi.org/10.1080/0284186X.2021.1898047 DOI: https://doi.org/10.1080/0284186X.2021.1898047
Epstein JI, Allsbrook WC, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–1242. https://doi.org/10.1097/01.pas.0000173646.99337.b1 DOI: https://doi.org/10.1097/01.pas.0000173646.99337.b1
Dansk Urologisk Cancer Gruppe. Danish Prostate Cancer Group DaProCa: annual report 2022. https://www.dmcg.dk/siteassets/arsberetninger-og-udgivelser/arsberetninger/2022/daproca-arsberetning-2022.pdf
Briganti A, Chun FKH, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol. 2006 Jun;49(6):1019–1027. https://doi.org/10.1016/j.eururo.2006.01.043 DOI: https://doi.org/10.1016/j.eururo.2006.01.043
Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012 Mar;61(3):480–487. https://doi.org/10.1016/j.eururo.2011.10.044 DOI: https://doi.org/10.1016/j.eururo.2011.10.044
Touijer KA, Sjoberg DD, Benfante N, et al. Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial. Eur Urol Oncol. 2021;4(4):532–539. https://doi.org/10.1016/j.euo.2021.03.006 DOI: https://doi.org/10.1016/j.euo.2021.03.006
Memorial Sloan Kettering Cancer Center pre-radical prostatectomy [Internet]. Available from: https://www.mskcc.org/nomograms/prostate/pre-op
Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7):30–33. https://doi.org/10.1177/1403494811401482 DOI: https://doi.org/10.1177/1403494811401482
Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. https://doi.org/10.1093/aje/kwq433 DOI: https://doi.org/10.1093/aje/kwq433
Arendt JFH, Hansen AT, Ladefoged SA, et al. Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin Epidemiol. 2020;12:469–475. https://doi.org/10.2147/CLEP.S245060 DOI: https://doi.org/10.2147/CLEP.S245060
Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7):26–29. https://doi.org/10.1177/1403494811399958 DOI: https://doi.org/10.1177/1403494811399958
Reticker-Flynn NE, Zhang W, Belk JA, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022;185(11):1924. https://doi.org/10.1016/j.cell.2022.04.019 DOI: https://doi.org/10.1016/j.cell.2022.04.019
Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822–832. https://doi.org/10.1056/NEJMoa1808424 DOI: https://doi.org/10.1056/NEJMoa1808424
Gentilini OD, Botteri E, Sangalli C, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023;9(11):1557–1564. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2809872
Lerner SP, Tangen C, Svatek RS, et al. SWOG S1011: a phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. J Clin Oncol. 2023 Jun 1;41(16_suppl):4508. https://doi.org/10.1200/JCO.2023.41.16_suppl.4508 DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.4508
Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):15–27. https://doi.org/10.1016/j.juro.2010.10.057 DOI: https://doi.org/10.1016/j.juro.2010.10.057
Touijer KA, Vertosick EA, Sjoberg DD, et al. Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection. Eur Urol. 2025 Feb 1;87(2):
253–260. https://doi.org/10.1016/j.eururo.2024.10.006 DOI: https://doi.org/10.1016/j.eururo.2024.10.006
Chow KM, So WZ, Lee HJ, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol. 2023 Jul 1;84(1):36–48. https://doi.org/10.1016/j.eururo.2023.03.001 DOI: https://doi.org/10.1016/j.eururo.2023.03.001
Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396(10260):1413–1421. Available from: http://www.thelancet.com/article/S0140673620315531/fulltext
Parker CC, Kynaston H, Cook AD, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. 2024 May 16 [cited 2024 May 29]. Available from: http://www.thelancet.com/article/S014067362400549X/fulltext
Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399(10338):
1886–1901. https://doi.org/10.1016/S0140-6736(21)01790-6 DOI: https://doi.org/10.1016/S0140-6736(21)01790-6
Briganti A, Karnes JR, Da Pozzo LF, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, E. Eur Urol. 2009;55(2):261–270. https://doi.org/10.1016/j.eururo.2008.09.043 DOI: https://doi.org/10.1016/j.eururo.2008.09.043
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Rikke Groth Olsen, William Birk Rich, Klaus Brasso, Andreas Røder, Lars Konge, Flemming Bjerrum, Hein Vincent Stroomberg
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
